Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ketamine
Biotech
NRx keeps antidepressant's blockbuster hopes alive despite flop
NRx's oral antidepressant has failed to reach statistical significance reducing depression severity in a phase 2/3 trial.
Gabrielle Masson
Apr 30, 2024 11:16am
Silo’s Alzheimer's ketamine med reduces dementia signs in mice
Jan 25, 2024 12:09pm
2 months after depression fail, Atai lays off 30% of staff
Mar 6, 2023 11:20am
FDA panel backs J&J’s ketamine-like depression drug
Feb 13, 2019 9:30am
J&J bags a second breakthrough tag for planned depression blockbuster
Aug 16, 2016 11:42am
